Skip to content
foodoseGet my numbers
ScienceJune 2, 20263 min read

Up to 47% lower breast cancer risk in GLP-1 users, and weight loss may not fully explain it

A study of more than 110,000 women presented at the ASCO cancer meeting found GLP-1 users were up to 47% less likely to develop breast cancer. Intriguingly, the weight loss alone did not appear to account for all of it.

What happened

At the 2026 meeting of the American Society of Clinical Oncology, researchers presented an analysis of more than 110,000 women and found that those taking a GLP-1 medication were substantially less likely to develop breast cancer, with one estimate reaching a 47% lower risk compared with non-users.

This sits alongside another 2026 study, published in Annals of Oncology, that found a similar drop, which we covered in depth in GLP-1s and cancer risk. Two large datasets now point the same way.

The genuinely new twist

The most interesting line in this study is a careful one: the protection may not be fully explained by weight loss alone. Researchers adjusted for how much weight women lost, and a benefit appeared to remain.

If that holds up, it points to something beyond the scale. The leading candidates are the same ones turning up across this year's research: lower inflammation, and changes in the hormone and insulin signalling that excess fat tissue drives. In other words, the drug may be quietting some of the biological signals that help breast cancer start, not just shrinking the fat that produces them. (More on that mechanism in how GLP-1s calm inflammation.)

Read it carefully

The usual, important caveats hold:

  • This is observational research. It shows a strong link, not proof that the drug caused the lower risk.
  • Lower risk is not no risk, and it changes nothing about your screening. Keep your mammograms exactly as your doctor advises.
  • This is not a reason to start, stay on, or stop a medication by yourself. A possible cancer benefit is a bonus, not a prescribing reason.

What it means for you

The honest takeaway is the calm one. A second large study now links these drugs to meaningfully lower breast cancer risk, and hints the protection runs deeper than weight. That is reassuring, especially for women, and it is one more entry in the growing list of things these medicines may do that the scale never shows.

What to do with this

Nothing in this changes what to eat tonight. What does not change either way is the protein floor, and the calculator sets it from your own numbers in about two minutes.

Work out yours

People also ask
Do GLP-1s lower breast cancer risk?
At the 2026 meeting of the American Society of Clinical Oncology, researchers presented an analysis of more than 110,000 women and found that those taking a GLP-1 were substantially less likely to develop breast cancer, with one estimate reaching a 47% lower risk compared with non users.
Is the breast cancer finding just explained by weight loss?
Possibly not, and that is the genuinely new part. Researchers adjusted for how much weight the women lost, and a benefit appeared to remain. The line in the study is a careful one, and it is worth reading as a hint rather than a conclusion.
How strong is the evidence that GLP-1s lower breast cancer risk?
It sits alongside another 2026 study published in Annals of Oncology that found a similar drop, so two large datasets now point the same way. Both are observational, which makes them good at spotting a link and unable to prove the drug caused it.
Read the originalASCO 2026 / JCO Oncology PracticeOpen
Go deeper

The news changes weekly. What protects your body doesn't.

Work yours out once: your calorie target, your protein floor, and three days of food built to them. Free, and no sign-up.

More from the Brief